McLeod Health has transformed pharmacy services into an integrated system of care, providing support to patients at every stage of treatment, recovery, and chronic disease management.
Pfizer Inc. today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results